The administration’s latest marijuana move is shaping up to be a tax story, with the most immediate implications centered on Section 280E and the companies that may finally get relief from it.
The US Department of Justice has taken a landmark step in drug policy by reclassifying certain marijuana products from Schedule I to Schedule III under the Controlled Substances Act.
Also part of the shift is language stating that the administrator “encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.”
Section 280E has long prevented cannabis businesses from deducting ordinary and necessary business expenses because marijuana remains federally restricted. That has left operators unable to write off costs such as payroll, rent, utilities, and advertising in the same way most businesses do, driving up effective tax burdens and pressuring margins across the industry.
The latest action could begin to change that, but only for a specific part of the market. The relief under discussion applies to state-licensed medical marijuana operators, not the broader adult-use cannabis sector. That distinction sharply narrows the scope of the potential benefit and leaves much of the US cannabis market outside the immediate tax relief path.
If Treasury were to act on the recommendation, the impact could extend beyond future filings. The language specifically raises the possibility of retrospective relief, meaning qualifying medical marijuana operators could potentially receive relief tied to prior taxable years in which they operated under a state medical marijuana license.
The limitation to medical marijuana also creates a new divide inside the cannabis trade. Operators with meaningful medical exposure may now be positioned to benefit sooner from lower tax pressure, while adult-use businesses remain subject to the existing federal framework. For multi-state operators with both medical and recreational operations, the revenue mix between those segments could take on greater importance.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
